Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DCK | P27707 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098907 | 1.00 | LMNA (0.37) | LMNADCK | |
| SCHEMBL9564683 | 0.71 | KDM4E (0.45) | — | |
| SCHEMBL9219025 | 0.68 | LMNA (0.67) | LMNA | |
| SCHEMBL16085075 | 0.68 | LMNA (0.67) | LMNA | |
| SCHEMBL9222430 | 0.68 | LMNA (0.67) | LMNA | |
| SCHEMBL9598928 | 0.68 | LMNA (0.45) | LMNA | |
| SCHEMBL2024502 | 0.66 | ADCY5 (0.37) | — | |
| SCHEMBL2024506 | 0.66 | ADCY5 (0.37) | — | |
| SCHEMBL2015100 | 0.66 | AHCY (0.38) | — | |
| SCHEMBL2015103 | 0.66 | AHCY (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093245-B2 | Anticancer agents; potent Deoxycytidine kinase inhibitors; inhibit thymidine kinase; inhibit uridine kinase; N-[3-(4-amino-5-fluoro-2-oxo-2H-pyrimidin-1-yl)-cyclopentyl]-3-bromo-benzenesulfonamide | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2121632-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080182847-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-07-31 | — | — | US | disclosed |
| WO-2008076778-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182847-A1 | 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE | TPMT, DHFR, GLS2 | LMNA 818/4885DCK 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.